Hemoglobin, Frailty, and Long-term Cardiovascular Events in Community-Dwelling Older Men Aged 70 Years

Sonali R Gnanenthiran1, Austin C C Ng1, Robert G Cumming2

  • 1Cardiology Department, Concord Repatriation General Hospital, Sydney, New South Wales, Australia; University of Sydney, Sydney, New South Wales, Australia; ANZAC Research Institute, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.

Insights

Low hemoglobin levels increase the risk of major adverse cardiovascular events (MACE) in older men, independent of frailty. A hemoglobin level of 140 g/L was identified as an optimal cutoff for predicting MACE.

Area of Science:

  • Gerontology
  • Cardiology
  • Hematology

Background:

  • Anemia is linked to higher mortality in older adults.
  • The connection between hemoglobin levels and major adverse cardiovascular events (MACE), and its modulation by frailty, remains unclear in older men.

Purpose of the Study:

  • To investigate the association between hemoglobin levels and 7-year MACE in community-dwelling older men.
  • To determine if frailty modifies the relationship between hemoglobin and MACE.

Main Methods:

  • Prospective analysis of 1604 men aged ≥ 70 years from the Concord Health and Ageing in Men Project (CHAMP).
  • Cox regression was used to analyze the relationship between hemoglobin and 7-year MACE.
  • Frailty was assessed using Fried criteria; the Youden index identified the optimal hemoglobin cutoff for MACE prediction.

Main Results:

  • Lower hemoglobin levels were associated with increased comorbidity, frailty, and MACE (P < 0.001).
  • A hemoglobin cutoff of 140 g/L was optimal for predicting MACE.
  • Each 10 g/L decrease in hemoglobin increased the risk of MACE (HR 1.13), all-cause mortality (HR 1.20), and cardiovascular mortality (HR 1.07).
  • The association between hemoglobin and MACE was independent of frailty (P = 0.24 for interaction).

Conclusions:

  • Low hemoglobin is an independent predictor of increased MACE in older men, irrespective of frailty.
  • A hemoglobin level of 140 g/L, exceeding typical anemia definitions, effectively predicts long-term MACE.
Abstract

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
12
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
3
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
72
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
11
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
2.8K